Serum C-peptide to plasma glucose ratio may be associated with efficacy of vildagliptin in Japanese patients with type 2 diabetes mellitus

Masami Tanaka, Risa Sekioka, Takeshi Nishimura, Toshihide Kawai, Shu Meguro, Junichiro Irie, Yoshifumi Saisho, Hiroshi Itoh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: This retrospective study was undertaken to clarify the characteristics of patients in whom vildagliptin exerts its HbA1c-lowering effect fully. The safety of vildagliptin was also examined. Methods: Vildagliptin was administered as initial, additive, or exchange medication to 139 type 2 diabetic patients. Patients were excluded if they had a change in another oral hypoglycemic agent within 24 weeks after starting vildagliptin. The primary efficacy endpoint was the percentage of patients who attained HbA1c level <7 % at week 24. Results: Vildagliptin significantly increased the percentage of patients who attained HbA1c level <7 %. It was significantly higher in patients with lower baseline HbA1c, higher C-peptide immunoreactivity (CPR) index [plasma CPR (ng/ml)/glucose (mg/dl) × 100], and in patients whose CPR index increased after the administration of vildagliptin. Categorical analyses by age, gender, and body mass index showed no significant differences among categories. There was no significant difference in HbA1c-lowering effect in the categories of oral hypoglycemic agents used concomitantly with vildagliptin, nor of hypoglycemic agents switched to vildagliptin. Logistic regression analyses indicated that the only factor contributing to the glucose-lowering effect of vildagliptin was baseline HbA1c. There were no changes in clinical parameters thought to be adverse events. Conclusions: Administration of vildagliptin provided a significant and clinically relevant HbA1c-lowering effect irrespective of age, gender, BMI, and concomitantly or previously used hypoglycemic agents. Furthermore, not only high baseline CPR index, but also the increase in CPR index may be associated with the efficacy of this medication.

Original languageEnglish
Pages (from-to)197-205
Number of pages9
JournalDiabetology International
Volume6
Issue number3
DOIs
Publication statusPublished - 2015 Sep 4

Fingerprint

C-Peptide
Type 2 Diabetes Mellitus
Glucose
Serum
Hypoglycemic Agents
vildagliptin
Body Mass Index
Retrospective Studies
Logistic Models
Regression Analysis
Safety

Keywords

  • C-peptide immunoreactivity
  • Predictive factor
  • Type 2 diabetes mellitus
  • Vildagliptin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Serum C-peptide to plasma glucose ratio may be associated with efficacy of vildagliptin in Japanese patients with type 2 diabetes mellitus. / Tanaka, Masami; Sekioka, Risa; Nishimura, Takeshi; Kawai, Toshihide; Meguro, Shu; Irie, Junichiro; Saisho, Yoshifumi; Itoh, Hiroshi.

In: Diabetology International, Vol. 6, No. 3, 04.09.2015, p. 197-205.

Research output: Contribution to journalArticle

@article{43d0e82dd0a94663b520db9e7f044191,
title = "Serum C-peptide to plasma glucose ratio may be associated with efficacy of vildagliptin in Japanese patients with type 2 diabetes mellitus",
abstract = "Aim: This retrospective study was undertaken to clarify the characteristics of patients in whom vildagliptin exerts its HbA1c-lowering effect fully. The safety of vildagliptin was also examined. Methods: Vildagliptin was administered as initial, additive, or exchange medication to 139 type 2 diabetic patients. Patients were excluded if they had a change in another oral hypoglycemic agent within 24 weeks after starting vildagliptin. The primary efficacy endpoint was the percentage of patients who attained HbA1c level <7 {\%} at week 24. Results: Vildagliptin significantly increased the percentage of patients who attained HbA1c level <7 {\%}. It was significantly higher in patients with lower baseline HbA1c, higher C-peptide immunoreactivity (CPR) index [plasma CPR (ng/ml)/glucose (mg/dl) × 100], and in patients whose CPR index increased after the administration of vildagliptin. Categorical analyses by age, gender, and body mass index showed no significant differences among categories. There was no significant difference in HbA1c-lowering effect in the categories of oral hypoglycemic agents used concomitantly with vildagliptin, nor of hypoglycemic agents switched to vildagliptin. Logistic regression analyses indicated that the only factor contributing to the glucose-lowering effect of vildagliptin was baseline HbA1c. There were no changes in clinical parameters thought to be adverse events. Conclusions: Administration of vildagliptin provided a significant and clinically relevant HbA1c-lowering effect irrespective of age, gender, BMI, and concomitantly or previously used hypoglycemic agents. Furthermore, not only high baseline CPR index, but also the increase in CPR index may be associated with the efficacy of this medication.",
keywords = "C-peptide immunoreactivity, Predictive factor, Type 2 diabetes mellitus, Vildagliptin",
author = "Masami Tanaka and Risa Sekioka and Takeshi Nishimura and Toshihide Kawai and Shu Meguro and Junichiro Irie and Yoshifumi Saisho and Hiroshi Itoh",
year = "2015",
month = "9",
day = "4",
doi = "10.1007/s13340-014-0186-7",
language = "English",
volume = "6",
pages = "197--205",
journal = "Diabetology International",
issn = "2190-1678",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Serum C-peptide to plasma glucose ratio may be associated with efficacy of vildagliptin in Japanese patients with type 2 diabetes mellitus

AU - Tanaka, Masami

AU - Sekioka, Risa

AU - Nishimura, Takeshi

AU - Kawai, Toshihide

AU - Meguro, Shu

AU - Irie, Junichiro

AU - Saisho, Yoshifumi

AU - Itoh, Hiroshi

PY - 2015/9/4

Y1 - 2015/9/4

N2 - Aim: This retrospective study was undertaken to clarify the characteristics of patients in whom vildagliptin exerts its HbA1c-lowering effect fully. The safety of vildagliptin was also examined. Methods: Vildagliptin was administered as initial, additive, or exchange medication to 139 type 2 diabetic patients. Patients were excluded if they had a change in another oral hypoglycemic agent within 24 weeks after starting vildagliptin. The primary efficacy endpoint was the percentage of patients who attained HbA1c level <7 % at week 24. Results: Vildagliptin significantly increased the percentage of patients who attained HbA1c level <7 %. It was significantly higher in patients with lower baseline HbA1c, higher C-peptide immunoreactivity (CPR) index [plasma CPR (ng/ml)/glucose (mg/dl) × 100], and in patients whose CPR index increased after the administration of vildagliptin. Categorical analyses by age, gender, and body mass index showed no significant differences among categories. There was no significant difference in HbA1c-lowering effect in the categories of oral hypoglycemic agents used concomitantly with vildagliptin, nor of hypoglycemic agents switched to vildagliptin. Logistic regression analyses indicated that the only factor contributing to the glucose-lowering effect of vildagliptin was baseline HbA1c. There were no changes in clinical parameters thought to be adverse events. Conclusions: Administration of vildagliptin provided a significant and clinically relevant HbA1c-lowering effect irrespective of age, gender, BMI, and concomitantly or previously used hypoglycemic agents. Furthermore, not only high baseline CPR index, but also the increase in CPR index may be associated with the efficacy of this medication.

AB - Aim: This retrospective study was undertaken to clarify the characteristics of patients in whom vildagliptin exerts its HbA1c-lowering effect fully. The safety of vildagliptin was also examined. Methods: Vildagliptin was administered as initial, additive, or exchange medication to 139 type 2 diabetic patients. Patients were excluded if they had a change in another oral hypoglycemic agent within 24 weeks after starting vildagliptin. The primary efficacy endpoint was the percentage of patients who attained HbA1c level <7 % at week 24. Results: Vildagliptin significantly increased the percentage of patients who attained HbA1c level <7 %. It was significantly higher in patients with lower baseline HbA1c, higher C-peptide immunoreactivity (CPR) index [plasma CPR (ng/ml)/glucose (mg/dl) × 100], and in patients whose CPR index increased after the administration of vildagliptin. Categorical analyses by age, gender, and body mass index showed no significant differences among categories. There was no significant difference in HbA1c-lowering effect in the categories of oral hypoglycemic agents used concomitantly with vildagliptin, nor of hypoglycemic agents switched to vildagliptin. Logistic regression analyses indicated that the only factor contributing to the glucose-lowering effect of vildagliptin was baseline HbA1c. There were no changes in clinical parameters thought to be adverse events. Conclusions: Administration of vildagliptin provided a significant and clinically relevant HbA1c-lowering effect irrespective of age, gender, BMI, and concomitantly or previously used hypoglycemic agents. Furthermore, not only high baseline CPR index, but also the increase in CPR index may be associated with the efficacy of this medication.

KW - C-peptide immunoreactivity

KW - Predictive factor

KW - Type 2 diabetes mellitus

KW - Vildagliptin

UR - http://www.scopus.com/inward/record.url?scp=84940758260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940758260&partnerID=8YFLogxK

U2 - 10.1007/s13340-014-0186-7

DO - 10.1007/s13340-014-0186-7

M3 - Article

VL - 6

SP - 197

EP - 205

JO - Diabetology International

JF - Diabetology International

SN - 2190-1678

IS - 3

ER -